Stenocare A/S banner
S

Stenocare A/S
CSE:STENO

Watchlist Manager
Stenocare A/S
CSE:STENO
Watchlist
Price: 1.415 DKK -0.35% Market Closed
Market Cap: kr61.4m

Relative Value

The Relative Value of one STENO stock under the Base Case scenario is 0.633 DKK. Compared to the current market price of 1.415 DKK, Stenocare A/S is Overvalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

STENO Relative Value
Base Case
0.633 DKK
Overvaluation 55%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Multiples Across Competitors

STENO Competitors Multiples
Stenocare A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Stenocare A/S
CSE:STENO
61.6m DKK 10.9 -2.5 -3.2 -3.2
US
Eli Lilly and Co
NYSE:LLY
986.9B USD 15.1 47.8 32.2 34.4
US
Johnson & Johnson
NYSE:JNJ
596.5B USD 6.3 22.3 15.4 19
CH
Roche Holding AG
SIX:ROG
293B CHF 4.8 31.2 13.1 15.3
CH
Novartis AG
SIX:NOVN
249.7B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
240.5B GBP 5.5 31.7 17.5 24.7
US
Merck & Co Inc
NYSE:MRK
305.9B USD 4.7 16.8 10.4 12.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.4 7.7 9
US
Pfizer Inc
NYSE:PFE
156.9B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 17.8 7.4 9.2
P/E Multiple
Earnings Growth PEG
DK
S
Stenocare A/S
CSE:STENO
Average P/E: 24.6
Negative Multiple: -2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.3
7%
3.2
CH
Roche Holding AG
SIX:ROG
31.2
29%
1.1
CH
Novartis AG
SIX:NOVN
23
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31.7
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.8
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
7%
1.5
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBITDA: 47.1
Negative Multiple: -3.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
15.4
2%
7.7
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17.5
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.4
3%
3.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBIT: 101.8
Negative Multiple: -3.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
22%
1.6
US
Johnson & Johnson
NYSE:JNJ
19
7%
2.7
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.6
CH
Novartis AG
SIX:NOVN
18.2
9%
2
UK
AstraZeneca PLC
LSE:AZN
24.7
21%
1.2
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
3%
3
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.2
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett